Business Description
Omeros Corp
NAICS : 325412
SIC : 2834
ISIN : US6821431029
Share Class Description:
OMER: Ordinary SharesDescription
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.75 | |||||
| Equity-to-Asset | -0.35 | |||||
| Debt-to-Equity | -1.71 | |||||
| Debt-to-EBITDA | -1.28 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 8.1 | |||||
| 3-Year EPS without NRI Growth Rate | -0.5 | |||||
| 3-Year Book Growth Rate | 40.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 13.69 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 66.29 | |||||
| 9-Day RSI | 63.5 | |||||
| 14-Day RSI | 59.42 | |||||
| 6-1 Month Momentum % | 24.44 | |||||
| 12-1 Month Momentum % | 262.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.41 | |||||
| Quick Ratio | 3.41 | |||||
| Cash Ratio | 2.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | 39.45 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -31.94 | |||||
| ROIC % | -87.26 | |||||
| 3-Year ROIIC % | -18.19 | |||||
| ROC (Joel Greenblatt) % | -819.13 | |||||
| ROCE % | -48.41 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -1.8 | |||||
| EV-to-Forward-EBIT | -0.6 | |||||
| EV-to-EBITDA | -1.81 | |||||
| EV-to-Forward-EBITDA | -0.6 | |||||
| EV-to-Forward-Revenue | 13.29 | |||||
| EV-to-FCF | -1.93 | |||||
| Earnings Yield (Greenblatt) % | -55.56 | |||||
| FCF Yield % | -63.54 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OMER
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Omeros Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.35 | ||
| Beta | 2.32 | ||
| Volatility % | 132.7 | ||
| 14-Day RSI | 59.42 | ||
| 14-Day ATR ($) | 0.19067 | ||
| 20-Day SMA ($) | 4.0185 | ||
| 12-1 Month Momentum % | 262.96 | ||
| 52-Week Range ($) | 1.05 - 5.68 | ||
| Shares Outstanding (Mil) | 57.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Omeros Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Omeros Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Omeros Corp Frequently Asked Questions
What is Omeros Corp(OMER)'s stock price today?
The current price of OMER is $4.22. The 52 week high of OMER is $5.68 and 52 week low is $1.05.
When is next earnings date of Omeros Corp(OMER)?
The next earnings date of Omeros Corp(OMER) is 2024-11-08 Est..
Does Omeros Corp(OMER) pay dividends? If so, how much?
Omeros Corp(OMER) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers